about our company

Driven by the Challenges.
Inspired by the Potential.

Recombinetics is a privately-held BioVenture company focused on solving some of the world’s most intractable challenges through gene editing.

through our ventures, we are:
  • Transforming the world across agricultural markets by developing and deploying safe and effective tools for these applications.
  • Using groundbreaking technology to improve and accelerate preclinical testing, making safer, more effective therapies.
  • Spearheading the improvement of patient outcomes in the field of organ transplantations and regenerative medicine.
Testing image
our story

From Innovator to Leader

Founded in 2008, Recombinetics focused its early-stage development on the application of precision genetic technologies in animals and active patent filings.

Today, Recombinetics is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.

We have a rich history as innovators and early adopters of molecular tools and methods for animal gene editing enhanced by incorporation of artificial intelligence. When paired with our experienced teams focused on bioinformatics, cell engineering, stem cell biology, and preclinical research, we’re able to add value to livestock and make pivotal changes in human health and longevity.

Recombinetics’ ever-expanding pipeline of gene-edited animals, products, and preclinical services, position the company for rapid growth in biomedical and food animal markets

a company of firsts

As leaders in the gene editing space, our global patent portfolio has grown to include potent gene editing methods and compositions with broad coverage for non-human species.

in Biomedicine

2024

First commercial launch of swine reporter models for gene therapy development

2024

First swine reporter models validated for in vivo gene editing

2023

First swine reporter models validated for in vivo gene therapy delivery

2023

First preclinical test performed in Therillume brain tumor models

2021-2022

First generation swine reporter models produced

2021

First inducible brain cancer models developed – foundation of Therillume

2020

First inducible liver cancer models developed

2008-2019

First to develop several pig models, including Neurofibromatosis Type 1 and Type 2, Ostogenesis imperfecta, and polycystic kidney disease

Discovery of new mechanism for human dilated cardiomyopathy in novel pig model

First to make APOBEC pigs for PERV-safe organs

in Gene Editing

2024

First patent allowance for multiplex gene editing in primary markets of USA and Brazil.

2023

First to develop serial multiplex editing in porcine stem cells

2022

First to develop serial multiplex editing in bovine stem cells

2019

First demonstration of in vivo somatic gene transfer in swine

2017

First patent issued in China for gene editing large animals

First patent issued in Europe for gene editing large animals

2016

First patent issued in the US for CRISPR gene editing in animals

2008-2015

First TALENs use to knockout and break genes in embryos

in Agriculture

2024

SLICK Angus progeny are born and raised in US

2023

First validation of reduced disease susceptibility to BVD in cattle

2023

First polled Wagyu are born in US

2023

Acceligen’s unique PRRSV resistance trait for swine is validated

2023

SLICK Holstein sire is determined non-GMO in Brazil

2022

FDA allows commercial use of first two SLICK Angus

2022

First Thamani Holstein is born derived from editing of multiple traits in bovine embryonic stem cells

2021

First non-GMO decision for heavy muscled Nelore bull in Brazil

2019

Bred first commercial slick Angus in US using CRISPR/Cas9 in embryos

2018

Demonstrated heat tolerance of SLICK for Angus clone in Brazil (bred by TALENs)

2017

Demonstrated durability of polled trait bred by gene editing

2015

First polled dairy animal prototype bred by TALENs (first HDR edited bovine – first use of gene editing in cattle as validation of non-genic variation for polled trait)

2013

Bred heavy muscled Nelore bull by embryo treatment with TALENs (first bovine animal edit)

peer-reviewed science

Our scientific findings are often published in peer-reviewed scientific journals and often cited by other scientists in their published research. Our Scientist are highly published and have been involved in over 74 publications, while employed at Recombinetics. See the link below for some of our highlights.

Your investment can help us change the world.

Reach out today for information on how you can make a difference.